AstraZeneca has secured European Union approval for a new pen injector formulation of Tezspire (tezepelumab), marking a significant advancement in severe asthma treatment accessibility. This novel delivery system will allow patients to self-administer the therapy at home, replacing the current healthcare worker-administered pre-filled syringe format.
The approval represents a crucial step forward in patient care, particularly significant as Tezspire stands as the first biologic therapy approved for severe asthma without specific biomarker or phenotype restrictions. The medication targets patients aged 12 and older with severe asthma who show inadequate response to high-dose inhaled corticosteroids plus another medication.
Clinical Evidence and Patient Access
The authorization builds on compelling data from two key studies: the PATH-BRIDGE phase 1 trial and the PATH-HOME phase 3 trial. Results demonstrated that 92% of healthcare providers, patients, and caregivers could successfully administer the treatment using the new device, maintaining efficacy comparable to the original formulation.
Dr. Mene Pangalos, AstraZeneca's head of biopharma R&D, emphasized the pen injector's role in supporting "a broad population of severe asthma patients." This broad applicability distinguishes Tezspire from other biological treatments such as Dupixent, Fasenra, Nucala, and Cinqaero, which have more restricted usage parameters.
Market Impact and Commercial Performance
The therapy's unique positioning has generated significant market interest, with analysts projecting potential annual sales exceeding $1 billion. Early market performance in the United States, where Amgen partners with AstraZeneca, has exceeded expectations. Third-quarter 2022 sales reached $55 million, contributing to a nine-month total of $91 million – substantially outperforming initial projections.
The treatment carries a U.S. list price of approximately $47,000 per year before discounts, notably higher than the Institute for Clinical and Economic Review's suggested "placeholder" price of $28,000. Despite this pricing, strong uptake indicates significant market demand and clinical value.
Future Prospects
While the EU leads with this approval, AstraZeneca anticipates FDA decision on the pre-filled pen in the first half of 2023. The therapy's potential impact is substantial, considering the estimated 2.5 million patients worldwide with uncontrolled severe asthma who could benefit from this treatment option.
The monthly dosing schedule, combined with the convenience of self-administration, positions Tezspire to potentially reshape the severe asthma treatment landscape, offering a more accessible and broadly applicable therapeutic option for patients with this challenging condition.
